55717-46-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-5-hydroxypyridine is used as a pharmaceutical compound for its antioxidant properties. It serves to protect human low-density lipoproteins from oxidative damage, which can contribute to the development of various diseases and health conditions.
Used in Chemical Research:
As a substituted pyridine, 2-Amino-5-hydroxypyridine is also utilized in chemical research for its unique structural and functional characteristics. It can be further modified or used as a building block in the synthesis of other complex molecules with potential applications in various industries.
Used in Antioxidant Formulations:
Due to its efficient antioxidant properties, 2-Amino-5-hydroxypyridine is used in the development of antioxidant formulations for various applications, such as in the food and cosmetic industries. These formulations help to extend the shelf life of products and protect them from oxidative degradation.

Upstream product

• 856835-98-8 5-hydroxy-pyridine-2-carboxylic acid hydrazide 
• 69634-17-9 N-(5-hydroxy-pyridin-2-yl)benzamide 
• 109-00-2 3-HYDROXYPYRIDINE 
• 35771-41-6 6-[2-(4-nitrophenyl)diazenyl]-3-pyridinol 
• 15069-92-8 5-hydroxypicolinic acid 
• 96166-00-6 5-phenylmethoxypyridin-2-amine 
• 1072-97-5 5-bromo-2-pyridylamine 
• 1267854-62-5 2-triphenylmethylamino-5-bromopyridine 
• 20511-12-0 2-amino-5-iodopyridine 
• 228710-82-5 5-bromo-2-(2,5-dimethyl-pyrrol-1-yl)-pyridine 
• 10167-97-2 2-amino-5-methoxypyridine 

Downstream Products

• 952066-41-0 9-hydroxy-6-(4-nitrophenyl)-pyrido[2',1':2,3]imidazo[4,5-c]isoquinolin-5(6H)-one 
• 50930-57-9 hydroxysulfapyridine 
• 134638-36-1 2-(5-phenyl-n-pentyl) amido-5-(5-phenylpentanoyl)oxypyridine 
• 1019582-87-6 5-(cyclohexyloxy)-2-aminopyridine 
• 1208331-21-8 C₂₄H₁₉N₃O₂ 
• 417722-21-5 5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridine-2-amine 
• 1558030-46-8 N-(5-((2-(3-(2-hydroxyethyl)-3-methylureido)pyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1558030-43-5 N-(5-((2-(3-(2-hydroxyethyl)ureido)pyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1558030-45-7 phenyl (4-((6-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido)pyridin-3-yl)oxy)pyridin-2-yl)carbamate 
• 1552280-99-5 3-chloro-4-((6-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido)pyridin-3-yl)oxy)picolinamide 
• 1558030-38-8 N-(5-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1552280-56-4 N-(5-((2-aminopyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1552280-97-3 4-((6-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido)pyridin-3-yl)oxy)picolinamide 

Relevant academic research and scientific papers

Novel pyridine bioisostere of cabozantinib as a potent c-met kinase inhibitor: Synthesis and anti-tumor activity against hepatocellular carcinoma

Two novel bioisosteres of cabozantinib, 3 and 4, were designed and synthesized. The ben-zene ring in the center of the cabozantinib structure was replaced by trimethylpyridine (3) and pyridine (4), respectively. Surprisingly, the two compounds showed extremely contrasting mesenchy-mal–epithelial transition factor (c-Met) inhibitory activities at 1 μM concentration (4% inhibition of 3 vs. 94% inhibition of 4). The IC50 value of compound 4 was 4.9 nM, similar to that of cabozantinib (5.4 nM). A ligand-based docking study suggested that 4 includes the preferred conformation for the binding to c-Met in the conformational ensemble, but 3 does not. The anti-proliferative activity of compound 4 against hepatocellular carcinoma (Hep3B and Huh7) and non-small-cell lung cancer (A549 and H1299) cell lines was better than that of cabozantinib, whereas 3 did not show a signifi-cant anti-proliferative activity. Moreover, the tumor selectivity of compound 4 toward hepatocellu-lar carcinoma cell lines was higher than that of cabozantinib. In the xenograft chick tumor model, compound 4 inhibited Hep3B tumor growth to a much greater extent than cabozantinib. The present study suggests that compound 4 may be a good therapeutic candidate against hepatocellular carci-noma.

METHOD FOR PRODUCING AMINO-HYDROXYPYRIDINE COMPOUND

PROBLEM TO BE SOLVED: To provide a method for producing an amino-hydroxypyridinium salt and an amino-hydroxypyridine compound with good yield and without using explosive hydroxylamine. SOLUTION: Provided is a method for producing an amino-hydroxypyridinium salt and an amino-hydroxypyridine compound via an aralkyloxy-pyridine compound represented by a formula (4). (In the formula, PG is a t-butoxycarbonyl group, a diphenylmethyl group, a triphenylmethyl group, a p-methoxyphenyl-diphenylmethyl group or a di(p-methoxyphenyl)phenylmethyl group, R1 is a hydrogen atom, an alkyl group or an alkoxy group, R2 represents a hydrogen atom, an alkyl group or an aryl group, and n is an integer of 1 or 2.) SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Synthesis of 2-amino-5-hydroxypyridine via demethoxylation

A convenient and efficient four-step synthesis of 2-amino-5-hydroxypyridine can be achieved by protective reaction of 2-amino-5-bromopyridine in the presence of 2,5-hexanedione to yield 5-bromo-2-(2,5-dimethyl-1H-pyrrol-1yl)pyridine, methoxylation with sodium methylate to give 5-methoxy-2-(2,5-dimethyl-1H-pyrrol-1yl)pyridine, deprotective reaction with hydroxylamine hydrochloride to produce 2-amino-5-methoxypyridine and demethylation with 95 % H2SO4 to afford the title compound in an overall yield of 45 %.

HIV INHIBITING 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES

HIV inhibitory compounds of formula (I) salts, hydrates, solvates, N-oxides, or stereoisomers thereof, wherein A forms pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, and thiadiazole; R1 is halo, cyano, nitro, C1-6alkyl, polyhaloC1-6alkyl, -C1-6alkyl-OR4, -C(=O)-R5, -C(=O)-OR4, -C(=O)-NR6R7, -OR4, -O-C(=O)-C1-6alkyl, -O-C1-6alkyl-OR4, -O-C1-6alkyl-NR6R7, -O-C1-6alkyl-O-C(=O)-C1-6Alkyl, -O-C1-6alkyl-C(=O)-OR4, -O-C1-6alkyl-C(=O)-NR6R7, -NR6R7, -NR8-C(=O)-R5, -NR8-C(=O)-OR4, -NR8-C(=O)-NR6R7, -NR8-C(=O)-C1-6lkyl-C(=O)-OR4, -NR8-C1-6alkyl-OR4, -NR8-C1-6alkyl-NR6R7, -NR8-C1-6alkyl-imidazo lyl, -NR8-SO2R9, -N=CH-NR6R7, -NH-C(=NH)-NH2, -SO2NR6R7, and -O-PO(OR8)2; D forms pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, pyrazole, furane, oxazole, isoxazole, thiophene, thiazole, and isothiazole; R2 is C1-6alkyl, polyhaloC1-6alkyl, halo, cyano, -COOR4, -OR4, and -NR6R7; R3 is phenyl, pyridyl, pyrimidinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, quinoline, imidazopyrimidinyl, pyrazolopyrimidinyl, triazolopyrimidinyl, pyridopyrimidinyl; which may optionally be substituted; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; 25 pharmaceutical compositions containing these compounds, methods for preparing these compounds and compositions.

CNS active compounds

Compounds of the formula STR1 wherein R may be hydrogen or a straight or branched chain alkyl radical of from 1 to 10 carbon atoms, aryl of from 6 to 10 carbon atoms, or aralkyl of from 7 to 10 carbon atoms; Y may be hydrogen, alkyl of from 1 to 4 carbons, CF3, F, Cl, or Br; and Z may be hydrogen or as defined hereinafter. These compounds are useful as central nervous system stimulants or more specifically in enhancing performance or as mood elevators.